Benjamin Pottebaum, DO
Gastroenterology · Clive, IANPI 1528419066
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,198 of the $5,829 with a category attached, or 89.2%. It is spread thinly across 27 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,372 and has fallen 99.9% since, to $2 in 2025. Among gastroenterology clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 212 payments — averaging $27.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Olympus Corporation Of The Americas$792
- Takeda Pharmaceuticals U.S.A., Inc.$592
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$486
- Johnson & Johnson$386
- Gilead$341
- plus $2K from 21 others
What the payments were for
- Travel & lodging$63111%
- Food & beverage$5,19889%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 54 | $1,316 |
| Olympus Corporation Of The Americas | 12 | $792 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $592 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 28 | $486 |
| Johnson & Johnson | 22 | $386 |
| Gilead | 10 | $341 |
| Regeneron Healthcare Solutions, Inc. | 10 | $291 |
| Ardelyx, Inc. | 8 | $272 |
| Janssen Scientific Affairs, LLC | 2 | $250 |
| Intercept Pharmaceuticals, Inc. | 2 | $241 |
| Boston Scientific | 1 | $125 |
| Portola Pharmaceuticals, LLC | 1 | $116 |
| Merck | 7 | $115 |
| Bristol Myers Squibb | 6 | $103 |
| Pfizer | 4 | $71 |
| Boehringer Ingelheim | 3 | $70 |
| Ironwood Pharmaceuticals, Inc | 4 | $58 |
| Sanofi | 2 | $49 |
| Baxter Healthcare | 1 | $29 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Braintree Laboratories, Inc. | 1 | $21 |
| Organon | 1 | $20 |
| Amgen | 1 | $17 |
| Shionogi Inc | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
| Redhill Biopharma Inc. | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVIS EXERA$560
- Olympus Capital Accessories$560
- ScopeGuide$560
- STELARA$250
- Epclusa$225
- Rinvoq$125
- GENERAL - BILIARY DEVICES$125
- DUPIXENT$122
- ANDEXXA$116
- OCALIVA$116
- IBSRELA$107
- Entyvio$101
How this compares
$5,829 in reported general payments places this provider in the 90th percentile of 113 gastroenterology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 47 | $27,448 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 238 | $15,581 |
| Mesalamine | 36 | $7,591 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 24 | $2,944 |
| Pantoprazole Sodium | 258 | $2,367 |
| Sucralfate | 55 | $2,020 |
| Omeprazole | 189 | $1,586 |
| Ondansetron Hcl | 325 | $854 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 31 | $519 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 37 | $400 |
| Metoclopramide Hcl | 25 | $214 |
| Nortriptyline Hcl | 11 | $89 |
| Amitriptyline Hcl | 12 | $27 |
| Prednisone | 18 | $16 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $1,316 | $27,44847 claims |
| Braintree Laboratories, Inc.Suflave | $21 | $2,94424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 113 gastroenterology providers in Iowa.
Other gastroenterology in Clive
- Nagendra MyneniClive$66K
- Bernard LemanClive$12K
- Archana VermaClive$6K
- Christopher MulderClive$6K
- Amol AgarwalClive$6K
- Tercio LopesClive$5K
- Ravi VemulapalliClive$4K
- Thomas MartinClive$2K
- Rajalakshmi IyerClive$2K
- Jeffrey BrannenClive$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.